Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2011 by The HIV Netherlands Australia Thailand Research Collaboration.
Recruitment status was  Recruiting
Information provided by:
The HIV Netherlands Australia Thailand Research Collaboration Identifier:
First received: June 4, 2010
Last updated: February 3, 2011
Last verified: February 2011

To assess safety, efficacy and impact of Lopinavir/ritonavir 400/100mg bid or Lopinavir/ritonavir 600/150mg bid in combination with rifampicin-containing anti-TB therapy.

Condition Intervention Phase
HIV Infections
Drug: LPV/r
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Official Title: A Pilot Study of the Pharmacokinetics and Safety of Lopinavir/Ritonavir 400/100mg Bid Versus Lopinavir/Ritonavir 600/150 mg BID Combined With Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV/TB Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy

Resource links provided by NLM:

Further study details as provided by The HIV Netherlands Australia Thailand Research Collaboration:

Primary Outcome Measures:
  • plasma concentration level [ Time Frame: 12 hours ] [ Designated as safety issue: Yes ]
    Percentage of plasma concentration level above an acceptable lower limit (lopinavir Cmin > 1 mg/L) at steady-state.

Secondary Outcome Measures:
  • toxicity [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
    Toxicity of combined treatment for TB and HIV infections - the established DAIDS/ACTG toxicity grading scale of clinical and laboratory toxicities will be used.

  • CD4 [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
    CD4 response (mean CD4 rise from baseline)

  • HIV RNA [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
    HIV RNA response (% < 50 copies/ml at week 12, 24 and 48)

  • genotypic resistant [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
    The emergence of NRTI and/or lopinavir genotypic resistant and its clinically

Estimated Enrollment: 40
Study Start Date: November 2010
Estimated Study Completion Date: July 2012
Estimated Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
boosted LPV/r 400/100 mg BID + 2 NRTI
Drug: LPV/r
LPV/r 400/100 mg BID + 2 NRTI for arm 1 (total 48 weeks) LPV/r 600/150 mg BID + 2 NRTI for arm 2 (total 48 weeks)
Experimental: 2
boosted LPV/r 600/150 mg BID + 2 NRTI
Drug: LPV/r
LPV/r 400/100 mg BID + 2 NRTI for arm 1 (total 48 weeks) LPV/r 600/150 mg BID + 2 NRTI for arm 2 (total 48 weeks)

Detailed Description:

Fixed dose combination of d4T+3TC+NVP (GPOvir) is widely used in Thai HIV infected since June 2002. The prevalence of NNRTI resistance has increased since 2005. Tuberculosis can develop following NNRTI-based regimen failure or after introduction of a new salvage regimen with a boosted PI (immune recovery syndrome). Although, Efavirenz based HAART is preferred in TB/HIV with rifampicin containing antituberculosis. However, Efavirenz could not be used in case of NNRTI failure, intolerance or toxicity. It remains unknown how to optimally treat HIV /TB in populations in which rifampicin has to be used. Moreover, Rifabutin which is recommended when use concomitant with boosted PI4, 5, is not feasible in Thailand and other developing countries due to cost, toxicity and dosing considerations. If ritonavir-boosted LPV demonstrates suitable pharmacokinetics, and is well tolerated, this regimen might prove extremely useful and could be widely implemented. LPV/r is potent and widely available boosted PI in National Health System in Thailand. We therefore believe that there is a strong rationale and impetus for the study of LPV/r 400/100 mg bid versus LPV/r 600/150 mg bid as a boosted-PI combination that in the presence of RMP, is able to produce a satisfactory PK profile associated with adequate antiretroviral potency, tolerability and efficacy .


Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Confirmed HIV positive after voluntary counseling and testing
  2. Aged >18-60years of age
  3. ARV naïve and NNRTI failure ( PI naive)
  4. CD4+ cell count of <350 cells/mm3 at the time of diagnosed TB
  5. ALT <5 times ULN
  6. Serum creatinine <1.4 mg/dl
  7. Hemoglobin >8 mg/L
  8. TB is diagnosed and planned to receive stable doses of rifampicin-containing anti-TB therapy for at least a 2 week period after initiation of ART
  9. No other active OI (CDC class C event), except oral candidiasis or disseminated MAC
  10. Able to provide written informed consent

Exclusion Criteria:

  1. Current use of steroid (except short course steroid for IRIS) and other immunosuppressive agents.
  2. Current use of any prohibited medications related to drug pharmacokinetics.
  3. Patients with current alcohol or illicit substance use that in the opinion of the site Principal Investigator would conflict with any aspect of the conduct of the trial.
  4. Unlikely to be able to remain in follow-up for the protocol defined period.
  5. Patients with proven or suspected acute hepatitis. Patients with chronic viral hepatitis are eligible provided ALT, AST < 5 x ULN.
  6. Karnofsky performance score <30%
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01138202

Contact: Anchalee Avihingsanon, MD 662-652-3040 ext 107
Contact: Thidarat Jupimai, BS 662-652-3040 ext 127

HIV-NAT Thai Red Cross AIDS Research Center Recruiting
Bangkok, Thailand, 10330
Contact: Anchalee Avihingsanon, MD    662-652-3040 ext 107   
Contact: Thidarat Jupimai, BS    662-652-3040 ext 127   
Principal Investigator: Anchalee Avihingsanon, MD         
Sponsors and Collaborators
The HIV Netherlands Australia Thailand Research Collaboration
Principal Investigator: Anchalee Avihingsanon, MD The HIV Netherlands Australia Thailand Research Collaboration
  More Information

Additional Information:
No publications provided

Responsible Party: Anchalee Avihingsanon, HIV-NAT Identifier: NCT01138202     History of Changes
Other Study ID Numbers: HIV-NAT 104
Study First Received: June 4, 2010
Last Updated: February 3, 2011
Health Authority: Thailand: Ethical Committee

Keywords provided by The HIV Netherlands Australia Thailand Research Collaboration:
rifampicin containing anti-tuberculosis therapy
Pharmacokinetics and safety of Lopinavir/ritonavir with rifampicin containing anti-tuberculosis therapy

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Actinomycetales Infections
Bacterial Infections
Gram-Positive Bacterial Infections
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Mycobacterium Infections
RNA Virus Infections
Retroviridae Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Antitubercular Agents
Reverse Transcriptase Inhibitors
Anti-Bacterial Agents
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antibiotics, Antitubercular
Antiviral Agents
Enzyme Inhibitors
HIV Protease Inhibitors
Leprostatic Agents processed this record on February 26, 2015